[Inhibition of platelet function in pediatric medicine (author's transl)].
The postulated importance of platelets in the pathogenesis of thromboembolic events has stimulated interest in drugs that inhibit platelet function. Clinical trials of antiplatelet agents in the secondary prevention of myocardial infarction and transient ischaemic attacks have so far been inconclusive. In children antiplatelet drugs area used on the evidence of nothing but anecdote. Optimum drug or combination of drugs and dosage are still controversial. Possible fruitful applications of platelet modifying agents such as aspirin and dipyridamole in paediatric nephrology and cardiology await further evaluation in prospective trials.
D000367:Age Factors; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D005921:Glomerulonephritis / Q000188:drug therapy; D006084:Graft Rejection; D006330:Heart Defects, Congenital / Q000188:drug therapy; D006350:Heart Valve Prosthesis; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy; D006801:Humans; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy; D006435:Renal Dialysis; D013927:Thrombosis / Q000517:prevention & control
D004176:Dipyridamole; D001241:Aspirin
Plättchenfunktionshemmung in der Kinderheilkunde.